Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: A multicenter randomized clinical trial

Lupus

Volumn 21, Issue 9, 2012, Pages 944-952

  Chen, W ^a   Liu, Q ^a   Tang, X ^a   Fu, P ^b   Liu, F ^b   Liao, Y ^c   Yang, Z ^c   Zhang, J ^d   Chen, J ^e   Lou, T ^a   Fu, J ^f   Kong, Y ^g   Liu, Z ^h   Li, Z ^a   Yu, X ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^d People's Hospital of Yunnan Province   (China)

^e FUZHOU GENERAL HOSPITAL   (China)

^f GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^g Department of Nephrology   (China)

^h FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

azathioprine; lupus nephritis; randomized controlled trial; Tacrolimus

Indexed keywords

AZATHIOPRINE; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AZATHIOPRINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 84863911479     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312442259     Document Type: Article

References (23)

1. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004 ; 350: 971-980 (Pubitemid 38269274)
2. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005 ; 14: 265-272 (Pubitemid 40559171)
3. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004 ; 50: 3934-3940 (Pubitemid 39643941)
4. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010 ; 69: 2083-2089
5. Abstracts of the 9th International Congress on SLE. June 24-27 2010. Vancouver, Canada. Lupus 2010; 19 Suppl 1: 1-185.
6. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895.
7. Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol. 2006 ; 1: 925-932
8. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011 ; 57: 235-244
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
10. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 ; 15: 241-250 (Pubitemid 38140764)
11. Sinclair A, Appel G, Dooley MA, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007 ; 16: 972-980
12. URL: http://clinicaltrials.gov/.
13. Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol. 1994 ; 21: 1468-1471 (Pubitemid 24261530)
14. Vercauteren SB, Bosmans JL, Elseviers MM, Verpooten GA, De Broe ME. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int. 1998 ; 54: 536-545 (Pubitemid 28357417)
15. Tse KC, Lam MF, Tang SC, Tang CS, Chan TM. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus. 2007 ; 16: 46-51 (Pubitemid 46178086)
16. Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008 ; 47: 1678-1681
17. Myung SJ, Yoo B, Lee KH, et al. A case of systemic lupus erythematosus developing two years after remission of thrombotic thrombocytopenic purpura. Korean J Intern Med. 1996 ; 11: 178-182
18. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000 ; 35: 904-914 (Pubitemid 30238204)
19. Textor SC, Wiesner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993 ; 55: 1332-1339 (Pubitemid 23183247)
20. Textor SC, Burnett JC, Romero JC, et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 1995 ; 47: 1426-1433
21. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nature medicine. 2008 ; 14: 931-938
22. Wang Y, Jarad G, Tripathi P, et al. Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol. 2010 ; 21: 1657-1666
23. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007 ; 72: 1429-1447 (Pubitemid 350197945)